Abstract
Memapsin 2 (β-secretase, BACE 1) processing of β-amyloid precursor protein is the first step in the pathway leading to the production of amyloid-β, thus, it is a major target for the development of inhibitor drug for the treatment of Alzheimerss Disease. Although there are distinctive advantages of this protease as a drug target, the development of drug-like memapsin 2 inhibitors has been somewhat slow since the cloning of the protease seven years ago. Here we review the progress of memapsin 2 inhibitor development using crystal structure-based design cycles. Recent progress has evolved the inhibitors into sizes sufficiently small to penetrate cell membranes and the blood-brain barrier yet retain potency for the inhibition of Aβ production in cultured cells and experimental animals. Such progress lends optimism that clinically useful memapsin 2 inhibitors will eventually be developed.
Current Alzheimer Research
Title: Memapsin 2 (Beta-Secretase) Inhibitors: Drug Development
Volume: 5 Issue: 2
Author(s): Arun K. Ghosh, Nagaswamy Kumaragurubaran, Ling Hong, Gerald Koelsh and Jordan Tang
Affiliation:
Abstract: Memapsin 2 (β-secretase, BACE 1) processing of β-amyloid precursor protein is the first step in the pathway leading to the production of amyloid-β, thus, it is a major target for the development of inhibitor drug for the treatment of Alzheimerss Disease. Although there are distinctive advantages of this protease as a drug target, the development of drug-like memapsin 2 inhibitors has been somewhat slow since the cloning of the protease seven years ago. Here we review the progress of memapsin 2 inhibitor development using crystal structure-based design cycles. Recent progress has evolved the inhibitors into sizes sufficiently small to penetrate cell membranes and the blood-brain barrier yet retain potency for the inhibition of Aβ production in cultured cells and experimental animals. Such progress lends optimism that clinically useful memapsin 2 inhibitors will eventually be developed.
Export Options
About this article
Cite this article as:
Ghosh K. Arun, Kumaragurubaran Nagaswamy, Hong Ling, Koelsh Gerald and Tang Jordan, Memapsin 2 (Beta-Secretase) Inhibitors: Drug Development, Current Alzheimer Research 2008; 5 (2) . https://dx.doi.org/10.2174/156720508783954730
DOI https://dx.doi.org/10.2174/156720508783954730 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Non-Antidepressant Long-term Treatment in Post-Traumatic Stress Disorder (PTSD)
Current Clinical Pharmacology A Review of Sodium Oxybate and Baclofen in the Treatment of Sleep Disorders
Current Pharmaceutical Design Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry Determination of Spatial and Temporal Distribution of Microglia by 230nm-High-Resolution, High-Throughput Automated Analysis Reveals Different Amyloid Plaque Populations in an APP/PS1 Mouse Model of Alzheimers Disease
Current Alzheimer Research Pharmacogenomics of COPD
Current Pharmacogenomics A Bibliometric Analysis of Recent Arab Countries Research Activities in Renewable Energy (1966-2014)
Recent Innovations in Chemical Engineering Proteomic-Based Biomarker Discovery with Emphasis on Cerebrospinal Fluid and Multiple Sclerosis
Current Pharmaceutical Biotechnology ABC Transporters and the Blood-Brain Barrier
Current Pharmaceutical Design Assessment of Persistent, Bioaccumulative and Toxic Organic Environmental Pollutants in Liver and Adipose Tissue of Alzheimer’s Disease Patients and Age-matched Controls
Current Alzheimer Research Current Outcomes and Future Perspectives of Cochlear Implants
Current Drug Therapy An Overview on the Search for Schizophrenia Biomarkers
CNS & Neurological Disorders - Drug Targets Progressions of Sleep, Memory and Depression Applicable to Psychoanalysis: A Review
Current Psychiatry Reviews Role of Brain NUCB2/nesfatin-1 in the Regulation of Food Intake
Current Pharmaceutical Design Structural Magnetic Resonance Imaging Findings in Posttraumatic Stress Disorder and Their Response to Treatment: A Systematic Review
Current Psychiatry Reviews Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs
Recent Patents on Inflammation & Allergy Drug Discovery Prevalence of Pre-Existing Risk Factors for Adverse Events Associated with Atypical Antipsychotics Among Commercially Insured and Medicaid Insured Patients Newly Initiating Atypical Antipsychotics
Current Drug Safety Music Therapy in the Management of Dementia
Current Psychiatry Research and Reviews New Perspectives for the Diagnosis of Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Abnormalities in Kynurenine Pathway Metabolism in Treatment-Resistant Depression and Suicidality: A Systematic Review
CNS & Neurological Disorders - Drug Targets Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response
CNS & Neurological Disorders - Drug Targets